

January 08, 2024

BSE Limited

Department of Corporate Relationship
1st Floor, New Trade Ring, Rotunda Building
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai- 400001
Scrip Code: 524742

National Stock Exchange of India Ltd.,

Department of Corporate Services
Exchange Plaza, 5th Floor,
C-1, Block G, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
Scrip Code: CAPLIPOINT.

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations') - Signing of Memorandum of Understanding

Pursuant to Regulation 30 of the SEBI Listing Regulations, we wish to inform you that the Company has entered into a Memorandum of Understanding (MoU) with Guidance, the Nodal Agency of Government of Tamil Nadu on 8th January 2024 as part of the Tamil Nadu Global Investors Meet 2024, Chennai. In this regard we enclose herewith the following: -

1. Annexure – A – Press Release
2. Annexure – B – Requisite details as required under the SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated July 11, 2023

Kindly take the same on record.

Thanking You,

Sincerely Yours

For Caplin Point Laboratories Limited

Venkatram G
General Counsel & Company Secretary
Membership No. A23989

Encl: A/a

Annexure – A

Caplin Group announces Strategic Investment of INR 700 Crores in Tamil Nadu

Chennai, January 08, 2024: Caplin Group of Companies is pleased to announce the signing of a Memorandum of Understanding (MoU) with the Tamil Nadu Government during the Tamil Nadu Global Investors Meet, 2024. This MoU outlines Caplin Group's commitment to invest INR 700 Crores over a period of 5 years in diverse projects. This investment will be made by Caplin Point Laboratories Limited and its subsidiaries - Caplin Steriles Limited and Caplin One Labs Limited.

The MoU specifies that the government will provide necessary infrastructure and regulatory assistance as per applicable laws. This will also enable the availing of standard incentives, subject to eligibility. The investments, spanning Oncology, Active Pharmaceutical Ingredients and R&D facilities, are projected to generate 1,500 employment opportunities (1,000 direct and 500 indirect).

Commenting on the achievement, Mr. C.C. Paarthipan, Chairman said:

“We are pleased to announce the signing of an MoU with the Government of Tamil Nadu. Aligned with the state's goals, our company's strategic investment emphasizes expanding manufacturing capabilities and driving research and development. This proactive approach not only empowers economic growth but also highlights our strong commitment to positive societal impact and social development. We appreciate the government's crucial role in ensuring the success of these key projects.”

About Caplin Point Laboratories Limited

Caplin Point Laboratories Limited is a fast-growing pharmaceutical company with a unique business model catering predominantly to emerging markets of Latin America and Africa. The Company has state of the art manufacturing facilities that cater to a complete range of finished dosage forms. Caplin Point is one of the few companies to show consistent high-quality growth in cashflows, Profitability and Revenues over the last 15 years.

Caplin Point has appeared on Forbes “Asia’s 200 Best Under a Billion” list for an unprecedented 6th time in the last 10 years and was awarded “The Emerging Company of 2018” and “Business Excellence Award for 2019” by Economic Times.

CAUTIONARY STATEMENT:

This press release contains certain forward-looking statements. Any forward-looking statement applies only on the date of this press release. By their nature, forward-looking statements are subject to a number of known and unknown risks and uncertainties that may or may not occur in the future and as a result of which the actual results and performance may differ substantially from the expected future results or performance expressed or implied in the forward-looking statements. No warranties or representations are made as to the accuracy, achievement or reasonableness of such statements, estimates or projections, and Caplin Point has no obligation to update any such information or to correct any inaccuracies herein or omission here from which may become apparent.

For details, please contact:

<p>Investor Relations at Caplin Mr G Venkatram (General Counsel & Company Secretary) Tel: +91 44 24968000 investor@caplinpoint.net</p> <p>Churchgate Partners Anvita Raghuram / Rajiv Pandya Churchgate Partners +91 22 6169 5988 caplinpoint@churchgatepartners.com</p>	<p>Registered Office Caplin Point Laboratories Limited 3rd Floor, Ashvich Tower, No. 3, Developed Plots Industrial Estate, Perungudi, Chennai – 600 096, Tamil Nadu, India. Tel: +91 44 2496 8000 CIN: L24231TN1990PLC019053 ISIN: INE475E01026 NSE Code: CAPLIPOINT BSE CODE: 524742 Website: www.caplinpoint.net</p>
--	---

Annexure – B

Sr. No.	Particulars	Details
1.	Details of the counterparties (including name and relationship with the listed entity);	The MoU is entered between Caplin Group of Companies (comprising of Caplin Point Laboratories Limited (“CPL”), Caplin Steriles Limited (“CSL”), Caplin One Labs Limited (“CoL”)) and Tamil Nadu Guidance, the nodal Agency of Government of Tamil Nadu (“GoTN”).
2.	Purpose of entering into the agreement	Investment of INR 700 Crores by Caplin Group over a period of 5 years in diverse projects generating 1,500 employment opportunities (1,000 direct and 500 indirect) and facilitation and support by GoTN.
3.	Shareholding, if any, in the entity with whom the agreement is executed	NIL
4.	Significant terms of the agreement (in brief);	The MoU specifies that the government will provide necessary regulatory assistance, infrastructure support and facilitation as per applicable laws.
5.	Extent and the nature of impact on management or control of the listed entity	NA
6.	Details and quantification of the restriction or liability imposed upon the listed entity	NA
7.	Whether, the said parties are related to promoter/promoter group/ group companies in any manner. If yes, nature of relationship	No
8.	Whether the transaction would fall within related party transactions? If yes, whether the same is done at “arm’s length”	No
9.	In case of issuance of shares to the parties, details of issue price, class of shares issued	NA

10.	Any other disclosures related to such agreements, viz., details of nominee on the board of directors of the listed entity, potential conflict of interest arising out of such agreements, etc	NA
11.	In case of rescission, amendment or alteration, listed entity shall disclose additional details to the stock exchange(s):	NA